patients with the resolution of all the symptoms. Antihistamine therapy is reported with resolution of the symptoms^{4,7} especially when associated with prednisone, but one patient reported a diminished quality of life⁸ and another one relapsed after 1 month from bladder catheter removal.7 Treatment with benralizumab reported with a clinical improvement both in outcome and follow-up8. Nonsteroidal antiinflammatory drugs, hydroxyurea, IFN-alpha, mepolizumab, imatinib and other tyrosine-kinase inhibitors, vincristine, 6busulfan. chlorambucil. mercantonutine. azathioprine. cyclosporine-A, cytarabine, methotrexate, immunoglobulins, and alemtuzumab were reported for the EC second line treatment.^{2,3,6,8}

In case of gross hematuria and/or lower urinary tract symptoms, HES manifested as EC should be considered in differential diagnosis. BMB and cystoscopy with biopsy should be performed to confirm the suspicion. Major, but not resolving, surgery should be avoided in favor of a conservative therapy. Hyperbaric therapy could be considered to treat EC hematuria and studied for additional indications, such as hematuria

Ethical statement

An institutional review board approval was not required as this was a single case. The patient provided informed consent.

Conflict of interest

The authors declare no conflicts of interest associated with this manuscript.

Registry and the Registration No. of the study/trial

Not applicable.

Author contributions

Franco Alchiede Simonato: Conceptualization; methodology; writing – original draft; writing – review and editing. Nicola Pavan: Conceptualization; formal analysis; writing – original draft. Mirko Pinelli: Conceptualization; supervision. Gabriele Tulone: Investigation; methodology; validation. Rosa Giaimo: Methodology; supervision; validation. Annamaria Martorana: Supervision; visualization; writing – review and editing. Alchiede Simonato: Conceptualization; investigation; supervision; writing – review and editing.

References

- 1 Hardy WR, Anderson RE. The Hypereosinophilic syndromes. Ann. Intern. Med. 1968; 68: 1220–9.
- 2 Rolla G, Fornero M. Ipereosinofilia e sindromi ipereosinofile. Riv Immunol E Allergol Pediatr. 2014: 14–24. https://www.riaponline.it/wp-content/uploads/ 2017/05/04_Rolla_Immunologia-1.pdf
- 3 Jiang P, Wang C, Jin B, Lin Y, Chen S. Eosinophilic cystitis in a patient with hypereosinophila syndrome: a case report. Exp. Ther. Med. 2014; 8: 49-51
- 4 Özdoğan EB, Tıras S, Camlar SA et al. An unusual cause of terminal hematuria in a child: eosinophilic cystitis. Can. Urol. Assoc. J. 2014; 8: e867–71.
- 5 Heers H, Ramaswamy A, Hofmann R. A case of Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) of the urinary bladder. *Urology* 2017; 108: 7–10.
- 6 Chia D. Eosinophilic cystitis and haematuria: case report of a rare disease and common presentation. *Int. J. Surg. Case Rep.* 2016; 24: 43–5.
- 7 Rossanese M, Palumbo V, Sioletic S, Crestani A, Giannarini G, Ficarra V. Surgical treatment of eosinophilic cystitis in adults: a report of two cases and a literature review. *Urol. Int.* 2019; 102: 122–4.
- 8 Cooke WD, Cooke AJT. Successful treatment of eosinophilic cystitis with benralizumab. *Urol. Case Rep.* 2020; 33: 101379.
- 9 Fuller TW, Dangle P, Reese JN et al. Inflammatory Myofibroblastic tumor of the bladder masquerading as eosinophilic cystitis: case report and review of the literature. *Urology* 2015; 85: 921–3.
- 10 Oscarsson N, Müller B, Rosén A et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019; 20: 1602–14.

Editorial Comment

Editorial Comment to A conservative treatment for eosinophilic cystitis

The authors described a case of difficult-to-diagnose eosinophilic cystitis (EC) that caused recurrent hematuria. EC is an inflammatory disease with eosinophilic infiltration of the bladder wall. Peripheral blood eosinophilia is frequently observed in patients with EC but is not shown in this case. A pooled analysis of 135 patients with EC reported that peripheral eosinophilia (defined as >5% of eosinophilia among leukocytes) occurred in 43% of patients.²

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The definition of hypereosinophilia (HE) includes blood eosinophilia and/or tissue eosinophilic infiltration or increased eosinophils (≥20% of all nucleated cells) in the bone marrow similar to this case; thus, EC is considered part of HE.³ Various HE etiologies have been listed, including infection, drugs such as tranilast, allergy, or parasites. Taking a detailed medical history, such as a foreign voyage or dietary supplement is important to clarify the cause of HE. Additionally, hematologic malignancies, such as chronic eosinophilic leukemia, can also cause HE; therefore, consultation with a hematologist should be considered if pathological findings of the bladder tissue obtained using transurethral resection show eosinophilic infiltration.

There is no consensus on the treatment for EC, and corticosteroids or antihistamines are commonly used, with a relatively favorable response (77%) as the initial treatment. However, recurrence commonly occurs, and one or more recurrence was observed in 28% of patients with EC treated by the initial treatment.² Therefore, follow-up using ultrasonography or cystoscopy might be necessary even in successfully treated patients with EC. Cyclosporine⁴ or cystectomy⁵ has been reported as a treatment for recurrent cases or cases showing resistance to initial treatment. Although EC is a benign disease and medical treatment can often achieve complete remission and bladder preservation, underlying diseases that cause EC should be considered, particularly in unresponsive cases for the initial medical treatment or patients with symptoms involving multiple organs.

Ikko Tomisaki M.D., Ph.D. Department of Urology, University of Occupational and Environmental Health, Kitakyushu City, Fukuoka, Japan ikko@med.uoeh-u.ac.jp

DOI: 10.1002/iju5.12539

Conflict of interest

The author declares no conflict of interest.

References

- 1 Simonato FA, Pavan N, Pinelli M et al. A conservative treatment for eosinophilic cystitis. IJU Case Rep. 2022; 6: 8-12.
- 2 van den Ouden D. Diagnosis and management of eosinophilic cystitis: a pooled analysis of 135 cases. Eur. Urol. 2000; 37: 386–94.
- 3 Valent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J. Allergy Clin. Immunol. 2012; 130: 607–12.
- 4 Adeleye O, Trickett JS, Wright BL, Khan A. Refractory eosinophilic cystitis controlled with low-dose cyclosporine therapy: a case report. *Urol. Case Rep.* 2021; 39: 101829.
- 5 Rossanese M, Palumbo V, Sioletic S, Crestani A, Giannarini G, Ficarra V. Surgical treatment of eosinophilic cystitis in adults: a report of two cases and a literature review. *Urol. Int.* 2019; 102: 122–4.